毕得医药
(688073)
| 流通市值：14.94亿 | | | 总市值：31.91亿 |
| 流通股本：4255.19万 | | | 总股本：9088.29万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 262,669,977.5 | 1,091,858,561.97 | 805,006,735.83 | 522,625,316.59 |
| 营业收入 | 262,669,977.5 | 1,091,858,561.97 | 805,006,735.83 | 522,625,316.59 |
| 二、营业总成本 | 225,411,993.32 | 940,546,450.07 | 654,533,379.99 | 409,834,164.7 |
| 营业成本 | 160,517,623.25 | 655,120,131.68 | 481,152,783.89 | 309,803,101.12 |
| 税金及附加 | 1,025,276.59 | 5,137,913.72 | 2,787,154.16 | 2,136,669.9 |
| 销售费用 | 31,440,807.65 | 127,062,863.22 | 88,537,705.65 | 55,694,900.1 |
| 管理费用 | 24,653,471.92 | 119,550,943.45 | 71,350,081.41 | 44,022,128.05 |
| 研发费用 | 15,420,297.35 | 63,227,409.3 | 41,143,681.3 | 26,776,177.2 |
| 财务费用 | -7,645,483.44 | -29,552,811.3 | -30,438,026.42 | -28,598,811.67 |
| 其中:利息费用 | 856,539.19 | 2,530,435.16 | 1,593,602.71 | 1,018,054.41 |
| 其中:利息收入 | 7,322,689.04 | 27,983,759.54 | 21,261,484.37 | 14,415,968.92 |
| 加:公允价值变动收益 | -1,221,398.52 | -12,632,140.39 | -14,119,146.13 | -12,327,068.23 |
| 加:投资收益 | 435,243.4 | 3,759,981.22 | 2,879,320.64 | 1,091,146.81 |
| 资产处置收益 | 432,182.38 | 438,709.58 | 115,253.39 | 82,880.04 |
| 资产减值损失(新) | -6,931,767.23 | -18,263,044.45 | -8,595,753.1 | -3,966,774.79 |
| 信用减值损失(新) | -330,959.49 | -4,994,469.72 | -4,607,320.98 | -3,792,300.66 |
| 其他收益 | 1,546,551.46 | 7,008,019.03 | 6,219,430.8 | 4,128,717.99 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 31,187,836.18 | 126,629,167.17 | 132,365,140.46 | 98,007,753.05 |
| 加:营业外收入 | 136,932.44 | 59,847.02 | 237,403.18 | 13,516.96 |
| 减:营业外支出 | 14,538.18 | 692,242.81 | 671,823.2 | 578,532.23 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 31,310,230.44 | 125,996,771.38 | 131,930,720.44 | 97,442,737.78 |
| 减:所得税费用 | 5,235,287.44 | 17,550,472.6 | 19,283,090.82 | 13,859,710.42 |
| 六、净利润 | 26,074,943 | 108,446,298.78 | 112,647,629.62 | 83,583,027.36 |
| 持续经营净利润 | 26,074,943 | 108,446,298.78 | 112,647,629.62 | 83,583,027.36 |
| 归属于母公司股东的净利润 | 26,074,943 | 109,571,788.68 | 113,398,686.46 | 83,810,379.15 |
| 少数股东损益 | - | -1,125,489.9 | -751,056.84 | -227,351.79 |
| (一)基本每股收益 | 0.29 | 1.21 | 1.25 | 0.92 |
| (二)稀释每股收益 | 0.29 | 1.21 | 1.25 | 0.92 |
| 八、其他综合收益 | -339,064.78 | 282,987.35 | -8,619,012.01 | -19,177,951.89 |
| 归属于母公司股东的其他综合收益 | -339,064.78 | 282,987.35 | -8,619,012.01 | -19,177,951.89 |
| 九、综合收益总额 | 25,735,878.22 | 108,729,286.13 | 104,028,617.61 | 64,405,075.47 |
| 归属于母公司股东的综合收益总额 | 25,735,878.22 | 109,854,776.03 | 104,779,674.45 | 64,632,427.26 |
| 归属于少数股东的综合收益总额 | - | -1,125,489.9 | -751,056.84 | -227,351.79 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-28 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |